Forte Biosciences, Inc.

NasdaqCM:FBRX Rapporto sulle azioni

Cap. di mercato: US$6.1m

Forte Biosciences Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Forte Biosciences has a total shareholder equity of $17.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $26.1M and $9.1M respectively.

Informazioni chiave

0%

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessin/a
ContantiUS$24.50m
Patrimonio nettoUS$16.96m
Totale passivitàUS$9.12m
Totale attivitàUS$26.08m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

Jul 17
We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Mar 14
Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Large Forte Biosciences shareholder scolds company board of directors

Aug 24

We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Aug 17
We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Forte Biosciences: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Aug 16

Forte Biosciences large shareholders make demands for company's future

Jul 07

We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

Dec 23
We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

Forte Biosciences files for $300M mixed shelf offering

May 28

Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

Mar 13
Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Jan 19
Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis

Dec 18

Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Nov 25
Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences readies equity offering

Oct 28

Analisi della posizione finanziaria

Passività a breve termine: FBRX's short term assets ($25.7M) exceed its short term liabilities ($9.1M).

Passività a lungo termine: FBRX has no long term liabilities.


Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: FBRX is debt free.

Riduzione del debito: FBRX has not had any debt for past 5 years.


Bilancio


Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: FBRX has less than a year of cash runway based on its current free cash flow.

Previsione Cash Runway: FBRX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 25.9% each year


Scoprire le aziende sane